Palatin Technologies Inc., the Cranbury-based biopharmaceutical company, has named three new senior executives, it announced Monday.
The company said it has appointed Dr. Michael B. Raizman as chief medical officer, James E. Hattersley as senior vice president of business development and J. Don Wang as vice president of product development.
“We are proud that we continue to attract the best and brightest minds who share our passion and approach to bringing impactful treatments to patients,” CEO and President Carl Spana said in a prepared statement. “We are at a critical stage in the advancement of our inflammatory and autoimmune programs, and we believe Dr. Raizman, Mr. Hattersley and Dr. Wang will significantly aid the company in responding to the evolving challenges in the market with agility, expertise and determination.”
Raizman, a physician specializing in ophthalmology, will provide leadership and direction across the entire product pipeline, the company said, including clinical validation, medical and regulatory affairs and overall clinical, medical and regulatory activities.
Hattersley, who has more than 25 years of experience in business and corporate development, will be responsible for all business development strategies for the company. He had been an SVP with Mission Pharmacal Co.
Wang, who has more than 25 years of experience in the chemical and pharmaceutical industry, will head all chemistry, manufacturing and control activities. He had been head of research & development for American Regent Inc.
